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All patients undergoing bowel resection experience postoperative ileus, a transient cessation of bowel motility that prevents
eﬀective transit of intestinal contents or tolerance of oral intake, to varying degrees. An anesthesiologist plays a critical role,
not only in the initiation of surgical anesthesia, but also with the selection and transition to eﬀective postoperative analgesia
regimens. Attempts to reduce the duration of postoperative ileus have prompted the study of various preoperative, perioperative,
and postoperative regimens to facilitate gastrointestinal recovery. These include modiﬁable variables such as epidural anesthesia
and analgesia, opioid-sparing anesthesia and analgesia, ﬂuid restriction, colloid versus crystalloid combinations, prokinetic drugs,
and use of the new peripherally acting mu-opioid receptor (PAM-OR) antagonists. Review and appropriate adaptation of these
multiplemodiﬁableinterventionsbyanesthesiologistsandtheirsurgicalcolleagueswillfacilitateimplementationofabest-practice
management routine for bowel resection procedures that will beneﬁt the patient and the healthcare system.
1.Introduction
An anesthesiologist plays a critical role not only in the ini-
tiation of surgical anesthesia but also in the selection
and transition to an eﬀective maintenance of postoperative
analgesia. All patients undergoing bowel resection (BR)
experience postoperative ileus (POI), a transient cessation
of bowel motility that prevents eﬀective transit of intestinal
contents or tolerance of oral intake, to varying degrees [1–3].
Clinically, POI is characterized by delayed passage of ﬂatus
and stool, bloating, abdominal distension, abdominal pain,
nausea, and vomiting and is associated with an increase in
postoperative morbidity and length of hospital stay (LOS)
[4].
Although the etiology of POI is complex (Figure 1), it
is primarily associated with the surgical stress response, an
acute inﬂammatory response associated with manipulation
of the bowel, and endogenous opioids secreted within the
gastrointestinal (GI) tract in response to surgical trauma [3–
7]. Opioid-based analgesia is widely used and considered
the standard of care for postoperative pain management [8–
12]. Opioids mediate analgesia by binding to mu-opioid
receptors in the central nervous system [13]; however, they
also bind to peripheral mu-opioid receptors in the GI tract
resulting in a disruption of the migrating motor complex
and propulsive motor activity associated with GI motility,
inhibition of intestinal ion and ﬂuid secretion, and an
increase in the overall GI transit time, thereby exacerbating
POI [9, 13].
Attempts to reduce the duration of POI have prompted
the study of various preoperative, perioperative, and post-
operative regimens to facilitate GI recovery. This review
focuseson theanesthetic managementroutines (e.g.,opioid-
sparing anesthesia and analgesia, epidural anesthesia and2 Advances in Preventive Medicine
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Figure 1: The multifactorial etiology of postoperative ileus (POI). Development of POI is multifactorial. Surgical incision and manipulation
of the intestines activate inﬂammatory and stress responses and endogenous opioids. Mast cells release vasoactive substances diﬀusing into
blood vessels. These substances increase mucosal permeability, allowing entrance of luminal bacteria or LPS into lymphatics or interaction
with resident macrophages. Damaged tissue also activates macrophages, increasing expression of proinﬂammatory genes. Stress causes
macrophages to release chemokines and inﬂammatory cytokines, which attract leukocytes to the intestinal muscularis. Large amounts of
nitric oxide and prostaglandins are released, which impair smooth muscle contraction. Endogenous opioids are released, which disrupt GI
transit and motility. Exogenous opioid analgesia also disrupts GI motility.
analgesia, and use of peripherally acting mu-opioid receptor
(PAM-OR) antagonists) that may result in reduced time
to gastrointestinal recovery and hospital length of stay.
Application of these interventions by anesthesiologists and
best practice management routines across the institution
may beneﬁt the patient and the healthcare system.
2. Discussion
2.1. Can We Modify the Anesthetic Routines to Minimize
POI?. The anesthesiologist can contribute to the design
and implementation of a best practices routine that deﬁnes
optimal management routines aimed at accelerating return
of GI function and minimization of patient discomfort
and costs. One of the ﬁrst key management decisions
the anesthesiologist can help guide is the prevention and
management of pain. Because opioid use is clearly linked to
a d v e r s eG Ie ﬀects, there is a general consensus that epidural
analgesia and other opioid-sparing techniques will improve
postoperative GI outcomes. The two most common tech-
niques currently used for management of postoperative pain
are epidural analgesia and intravenous patient-controlled
analgesia (IV-PCA). Epidural analgesia is generally initiated
in the perioperative period and continued throughout the
postoperative period for up to 3 postoperative days [8].
Gastrointestinal function was reported in several studies to
return 48 to 72 hours earlier in patients receiving thoracic
epidural anesthesia and postoperative epidural analgesia
compared with patients receiving IV-PCA [10–12]. Thoracic
epidurals with local anesthetic (i.e., bupivacaine) signiﬁ-
cantly reduced duration of POI compared with systemic
opioid therapy in patients undergoing abdominal surgery
in randomized trials with comparable pain management
(P<. 05) [14–18]. Epidural bupivacaine compared with
epidural opioids alone or epidural bupivacaine and mor-
phine combinations signiﬁcantly reduced the incidence of
postoperative nausea and vomiting (P<. 01) [19], reduced
time to ﬁrst bowel movement [20], and signiﬁcantly reduced
time to GI recovery (P<. 005) [17] in multiple double-blind
studies [18]. Alternatively, when a fast-track postoperative
care pathway was used in a recent, randomized controlled
trial (N = 56) using either thoracic epidural analgesia with
b u p i v a c a i n ea n df e n t a n y lf o r2d a y sv e r s u sI V - P C At h a t
included opioid-sparing ketorolac, comparable outcomes
were obtained for length of stay, pain scores, quality of life,
complications, and hospital costs [21].
2.1.1. Opioid-Sparing Analgesia. The strategy to ameliorate
negativeeﬀectsofopioidsontheGItractinthepostoperative
period (e.g., POI and postoperative nausea and vomiting
(PONV)) is often best managed by simply reducing patient
exposure to opioids. In a metaanalysis of 52 random-
ized placebo-controlled trials comparing nonsteroidal anti-
inﬂammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2)
inhibitors, and acetaminophen administered in conjunction
with morphine after surgery, morphine consumption wasAdvances in Preventive Medicine 3
reduced 15% to 55% compared with morphine alone.
Moreover, NSAIDs administered in conjunction with mor-
phine reduced the incidence of nausea and vomiting from
28.8% to 22.0% compared with morphine alone [22]. In
a randomized, double-blind, placebo-controlled study of
total hip arthroplasty, addition of COX-2 inhibitors reduced
morphine consumption by 40.5% [23] .I n2p r o s p e c t i v e ,
randomized, double-blind studies in patients undergoing
colorectal surgery, the addition of ketorolac to morphine
IV-PCA had an opioid-sparing eﬀect (patients adminis-
tered ketorolac received 18.3% to 29% less morphine than
patients with comparable pain scores who self-administered
morphine alone via PCA) [24, 25]. However, the eﬀect of
ketorolac on time to ﬁrst bowel movement was not always
consistent. In 1 study, time to ﬁrst bowel movement was
signiﬁcantly improved in patients who received ketorolac
plus morphine compared with morphine alone, (ketorolac
plus morphine, 1.8 days; morphine, 2.4 days; P<. 001), and
patients who received morphine alone had a 5.25 greater risk
of developing POI [25]. However, in the second study the
addition of ketorolac did not improve time to ﬁrst bowel
movement (ketorolac and morphine, 1.5 days; morphine,
1.7 days; P<. 05) or time to ﬁrst ambulation (ketorolac
and morphine, 2.2 days; morphine, 2.8 days; P<. 05)
[24]. Additional larger prospective trials are required to
determine the beneﬁts of ketorolac on POI. Continuous
infusion of lidocaine to augment postoperative analgesia also
can reduce the need for opioids, and a metaanalysis review of
8publishedtrialsprovidesdemonstratedbeneﬁtsinreducing
the duration of POI [26].
Gabapentin, a calcium channel modulator, (1,200mg by
mouth 1 hour before surgery) reduced opioid consump-
tion after abdominal surgery compared with placebo in 2
randomized, double-blind trials [27, 28]. Morphine and
tramadol consumption after abdominal hysterectomy were
reduced in randomized, double-blind, placebo-controlled
studies after administration of gabapentin compared with
placebo (morphine was reduced by 20mg; P<. 001;
tramadol was reduced by 149mg over 24 hours) [27, 28].
Administration of oral gabapentin preoperatively and 24
hours postoperatively reduced morphine consumption by
32% compared with placebo without substantially aﬀect-
ing pain scores in patients undergoing hysterectomy [27].
Fentanyl consumption, as a rescue analgesic, was also
reduced in patients undergoing laparoscopic cholecystec-
tomy who received gabapentin in a randomized, double-
blindstudy[29].However,theeﬀectofthisandotheropioid-
sparing techniques (e.g., oﬀ-label use of the alpha-2 agonist
dexmedetomidine as a single loading dose or a continuous
infusion perioperatively) on POI has yet to be speciﬁcally
measured. These and other compounds may exert more
direct eﬀects on duration of POI, beyond the opioid-sparing
beneﬁt, when administered as part of a multimodal analgesic
approach.
Tapentadol, a centrally acting synthetic opioid analgesic,
has been approved for use in patients with moderate to
severe acute pain [30]. Although the exact mechanism of
action is not known, the analgesic eﬀect of tapentadol may
be attributed to mu-opioid agonist activity and inhibition
of norepinephrine reuptake [30]. The aﬃnity of tapentadol
for mu-opioid receptors is 18-times lower than that for
morphine; however, tapentadol is only 2 to 3 times less
potent in producing analgesia in animal models [30–32]. In
a randomized, double-blind, placebo- and active-controlled
study, tapentadol 50mg demonstrated similar pain relief
after orthopedic surgery and produced signiﬁcantly less
nausea and/or vomiting compared with oxycodone IR
10mg [33]. Tapentadol has not been speciﬁcally studied for
reducing the duration of POI; however, its opioid-sparing
analgesic eﬀect could potentially provide beneﬁt in the
context of a multimodal pathway.
2.1.2. Epidural Anesthesia. All anesthetics used for induction
ormaintenanceofgeneralanesthesiamaydepressGImotility
[8, 34]. When choosing an anesthetic regimen, the decision
to include epidural anesthesia, insertion location of the
epidural, selection of inhaled anesthesia agents, use of
neuromuscular reversal agents, the extent of the eﬀects of the
regimens on the GI tract, and GI recovery should be consid-
ered[8,35].Diﬀerencesinthesemultipleanestheticvariables
in previous studies also help to explain the conﬂicting results
of the eﬀects of anesthesia on the GI tract and may aﬀect the
duration of POI demonstrated across studies [8, 35].
Location of epidural placement, selection of the epidural
infusion mixture, and timing of the ﬁrst epidural bolus
dose are important factors for the risk of developing
POI. In abdominal surgeries such as colon resection, the
positive eﬀect of an epidural local anesthetic may only be
evident when administered in the thoracic region, as it is
related to segmental visceral aﬀerent/eﬀerent blockade [8].
In general, thoracic epidural analgesia is associated with
improved GI recovery compared with lumbar or systemic
analgesia [12]. Numerous studies using lumbar or low-
thoracic epidural administration of local anesthetics have
failedtodemonstratethepositiveeﬀectsofepiduralanalgesia
on the reduction of the duration of POI [16, 17, 36–38].
Low thoracic (T9 to T12) epidural blockade or dosing of
the epidural only after the surgical procedure is completed
may not permit suﬃcient dermatomal blockade of noxious
stimuli to eliminate development of a prolonged inhibition
of GI motility and facilitate a posttraumatic rapid return to
normal function [8].
2.1.3. Perioperative Fluid Administration. Perioperative ﬂuid
is administered to meet hourly ﬂuid requirements and to
replace ﬂuids lost during surgery [39]. However, excess
perioperative ﬂuid administration may lead to edema of the
GItract,resultinginprolongedileus[40].Postoperativeileus
was reduced in a small, randomized study (N = 20) in
patients undergoing colonic surgery who were placed under
ﬂuid restriction (≤2L water and 77mmol sodium per day)
during surgery compared with patients who received more
liberal ﬂuid management (≥3L water and 154mmol sodium
per day) [41]. In this study, positive salt and water balance
suﬃcient to cause a 3-kg weight gain delayed return of GI
function (median passage of ﬂatus 1 day later and laxation
2.5 days later than patients who received restricted ﬂuids)4 Advances in Preventive Medicine
and hospital discharge (9 postoperative days for patients
who received liberal ﬂuids versus 6 postoperative days for
patients who received restricted ﬂuids). Furthermore, in a
larger randomized study (N = 152), patients who received
liberal ﬂuids had a signiﬁcantly longer time to ﬁrst passage
of ﬂatus (Lactated Ringer’s 12mL/kg/hr, 4 days; Lactated
Ringer’s 4mL/kg/hr, 3 days; P<. 001) or bowel movement
(Lactated Ringer’s 12mL/kg/hr, 6 days; Lactated Ringer’s
4mL/kg/hr ,4days;P<. 001) and were discharged from the
hospital 1 day later (Lactated Ringer’s 12mL/kg/hr, 9 days;
Lactated Ringer’s 4mL/kg/hr, 8 days; P = .01) than patients
who received restrictive ﬂuids [42]. There were signiﬁcantly
more perioperative complications in patients who received
liberal ﬂuids (n = 23) compared with patients who received
restricted ﬂuids (n = 13; P<. 05); however, there were more
episodes of hypotension in patients who received restricted
ﬂuids (36 episodes in 20 patients) compared with patients
who received liberal ﬂuids (1 episode in 1 patient) [42].
The use of crystalloid infusions rather than colloids may
also predispose patients to excessive intestinal edema [43]. In
as m a l l ,r a n d o m i z e ds t u d y( N = 18), intestinal edema was
demonstrated in patients who received crystalloids during
surgery and not in patients who primarily received colloids
during surgery [43]. However, while use of ﬂuid restriction
rather than liberal ﬂuid administration to replace ﬂuids
lost during surgery is recommended, this technique has
not entered routine clinical use [39]. Further investigations
of ﬂuid restrictions, as well as crystalloids and colloid
combinations, are necessary to reach a ﬁnal consensus on
optimal ﬂuid resuscitation and maintenance routines.
2.1.4. Pharmacologic Treatments. Activation of the inducible
form of nitric oxide synthase (iNOS) directly modu-
lates intestinal dysmotility after bowel manipulation and
is involved in the initiation of intestinal inﬂammation
[5]; therefore, inhibition of iNOS may play a role in
reducing duration of POI. In a recent preclinical study,
S-methylisothiourea sulfate, an iNOS inhibitor, improved
small intestine motility in a canine postoperative model after
surgical intestinal manipulation [44]. Further studies are
warranted.
Prokinetic agents accelerate gastric emptying or colonic
transit and may, therefore, reduce the duration of POI
[45]. There are many subclasses of prokinetic agents that
theoretically address the multifactorial etiology of POI,
including acetylcholinesterase inhibitors, somatostatin ana-
logues, and receptor agonists and antagonists. However,
despite promising preclinical data, overall, prokinetic agents
have generally failed to demonstrate clinical eﬃcacy in
the management of POI, and additional agents are being
investigated [46].
Phase I studies have demonstrated that neostigmine,
an acetylcholinesterase inhibitor, increases postoperative
colonic motility and tone in healthy volunteers and patients
undergoing colorectal surgery [47]. Preclinical studies on the
somatostatin analogue octreotide demonstrated increased
intestinal motility in dogs after small-bowel autotransplan-
tation and amelioration of POI [48, 49]. Receptor-speciﬁc
compounds (e.g., serotonin and motilin receptor agonists,
dopamine and cholecystokinin-1 [CCK-1] receptor antag-
onists) have also demonstrated some motility-promoting
activity [45, 50, 51]. Although multiple serotoninergic ago-
nists (i.e., cisapride, tegaserod, and renzapride) have demon-
strated eﬃcacy in promoting GI motility, their beneﬁcial
eﬀects are limited because of serious adverse side eﬀects [52–
54].
Although the antibiotic erythromycin, a motilin receptor
agonist, stimulated gastric motility in healthy volunteers
[45, 55–57], erythromycin failed to demonstrate any beneﬁt
in the management of POI after abdominal surgery [58], and
erythromycin did not reduce the rate of nausea, vomiting,
or nasogastric tube (NGT) placement in patients after
colorectalsurgeryinarecentrandomizeddouble-blindstudy
[59]. Numerous studies have failed to demonstrate any
beneﬁt of metoclopramide in the management of POI [60–
62]. Despite promising preclinical data, overall, prokinetic
agents generally fail to demonstrate clinical eﬃcacy in the
management of POI, and additional agents are needed [46].
2.2. Are the Opioids the Real Culprits in POI? All patients
undergoing major abdominal surgery are at risk for POI [1–
3]. Although the etiology of POI is complex (Figure 1), it is
primarily associated with surgical trauma and manipulation
of the bowel, inhibitory neural reﬂexes, secretion of
endogenous opioids within the GI tract, and exogenous
opioid-based analgesia [4–6, 9, 63–66]. Surgical trauma and
manipulation activate inhibitory sympathetic neural reﬂexes
in the GI tract and induce the release of catecholamines,
inﬂammatorymediators,andendogenousopioids.Increased
levels of endogenous opioids during surgical trauma to the
bowel contribute to impaired GI motility, GI secretions, and
POI [5, 13, 67].
Opioid-based analgesia is widely used and considered
the standard of care for postoperative pain management [9,
13, 68]. Opioids mediate analgesia by binding to mu-opioid
receptors in the central nervous system [13]; however, they
also bind to peripheral mu-opioid receptors in the GI tract,
resulting in a disruption of the migrating motor complex
and propulsive motor activity associated with GI motility,
inhibition of intestinal ion and ﬂuid secretion, and an
increase in the overall GI transit time, thereby exacerbating
POI [9, 13].
2.3. Do the PAM-ORs Really Reduce POI? Peripherally acting
mu-opioid receptor antagonists, such as the FDA-approved
alvimopan and investigational methylnaltrexone, do not
appear to reverse central opioid action and may give anes-
thesiologists and surgeons the option of using preemptive
opioid analgesics without substantial opioid-associated GI
adverse eﬀect [9, 69–79]. Methylnaltrexone has been stud-
ied predominantly in patients with opioid-induced bowel
dysfunction. More recent clinical studies have reported
laxation and reduced oral-cecal transit times after multiple
doses of methylnaltrexone in patients with opioid-induced
constipation because of methadone maintenance therapy
[71, 80]. Methylnaltrexone also reversed opioid-inducedAdvances in Preventive Medicine 5
Table 1: Components of a multimodal management pathway for patients undergoing bowel resection.
Pathway component Beneﬁt—issues
Preoperative patient education and optimization of medical illness
and nutritional status
Reduce preoperative anxiety, minimize perioperative risks, and
enhance postoperative recovery [103, 104]
(i) Evaluation and discussion of operative anesthetic plan and
perioperative pain management program
Assurance of adequate pain control and selection of appropriate pain
management techniques will help with process of controlling
sympathetic reﬂexes, aﬀerent pain and stress-released neuropeptides,
and multiple factors contributing to motility inhibition [105]
(ii) Assessment of pain tolerance, history of current and past
opiate use and tolerance
Epidural should be thoracic and utilize local anesthetic infusion
initiated early during the surgical procedure to minimize any
responsiveness [50]
Epidural anesthesia and postoperative analgesia
Insertion and management of epidural must be coordinated with
plans for perioperative DVT prophylaxis (e.g., subQ heparin) [11]
IV-PCA
Patients with history of chronic opioid use will likely beneﬁt from use
of adjuncts or local anesthetic epidural in combination with IV-PCA
to avoid acute withdrawal symptoms [108]
Opioid-sparing adjuncts such as NSAIDs, dexmedetomidine,
lidocaine infusion, and gabapentin
Patients with history of opioid intolerance (e.g., PONV, constipation,
POI) may beneﬁt from opioid-sparing technique(s) and the addition
of PAM-OR antagonists [27, 102, 111, 115]
Patients with planned IV-PCA or opioid tolerance problems
evaluated for preoperative initiation of PAM-OR antagonists
PAM-OR antagonists will reverse adverse eﬀects of opioids on GI
function without compromising analgesia;
PAM-OR antagonists contraindicated in patients on chronic opioids
[83]
Preoperative antiemetics and gastric antacids/emptying
Optimize option of early NGT removal at end of procedure;
consider 5HT3, metoclopramide, and dexamethasone [110, 112]
Preoperative warming blankets and anxiolysis as needed
Reduce intraoperative hypothermia, and reduce preinduction stresses
[35]
Laparoscopic surgery
Reduced manipulation and trauma of the bowel leads to less
sympathetic activation and inﬂammation;
reduce postoperative pain and associated opioid use [113]
Limited NGT use postoperatively
Utilize intraoperatively but remove at end of procedure as discussed
for each case with surgeon;
allows resumption of early oral intake [109]
Minimize intraoperative ﬂuids and consider colloid
administration
Reduce bowel edema and accelerate GI recovery [43]
Early oral/enteral/sham (gum chewing) feeding initiated POD1 Stimulation of GI hormones [95]
Minimize postoperative opioids
Use of nonopioid analgesics and transition from IV-PCA if used to
oral agents when possible with IV opioids used only for breakthrough
severe pain [89]
Advancing of diet as tolerated
If clear liquids tolerated on POD1 then advance to soft diet POD2
[86]
Postoperative laxatives Help to induce bowel movement [114]
Early ambulation
Helps to prevent postoperative complications such as thrombosis,
atelectasis, and pneumonia [106]
Discharge planning communication
Will need to work toward multiple components to have patient
achieve toleration of adequate oral intake without PONV, adequate
pain control, evidence of lower GI activity (stool or gas per surgeon
routine), independent ambulation, and adequate support available at
home [107]
Abbreviations: DVT: deep vein thrombosis; GI: gastrointestinal; IV-PCA: intravenous patient-controlled analgesia; NGT: nasogastric tube; NSAIDS:
nonsteroidal anti-inﬂammatory drugs; PAM-OR: peripherally acting mu-opioid receptor; POD: postoperative day; POI: postoperative ileus; PONV:
postoperative nausea and vomiting; subQ: subcutaneously; TID: three times daily.6 Advances in Preventive Medicine
constipation in patients undergoing chronic opioid treat-
ment for oncologic pain [81]. Intravenous methylnaltrexone
(0.3mg/kg) accelerated GI recovery (methylnaltrexone, 124
hours; placebo, 151 hours; P = .06) and discharge time
(methylnaltrexone, 140 hours; placebo, 165 hours; P = .09)
in a recent phase II POI trial in patients undergoing segmen-
tal colectomy via laparotomy [73]. Opioid consumption was
comparable for methylnaltrexone and placebo groups [73].
According to a 2008 Wyeth news press release, a multicenter
phase III trial to investigate the eﬃcacy of methylnaltrexone
(12 to 24mg/kg intravenous every 6 hours) in patients
undergoing bowel resection via laparotomy did not meet
the primary endpoint of decreased time to GI recovery after
bowel resection, or its secondary endpoints, including time
to discharge eligibility [82].
Alvimopan is an oral PAM-OR antagonist with low
bioavailability (6%) that was approved by the FDA in 2008
for the management of POI [83]. Alvimopan accelerated
time to GI recovery and time to hospital discharge order
written compared with placebo in 4 North American phase
III trials of POI in patients undergoing bowel resection via
laparotomy receiving opioid-based IV-PCA [72, 74, 77–79].
In a ﬁfth phase III trial that was conducted in Europe, the
beneﬁts of alvimopan were seen in a post hoc subgroup
analysis of patients who received opioid-based IV-PCA for at
least the ﬁrst 48 hours after surgery [76]. Consistent with the
role of opioids in the pathoetiology of POI, acceleration of
GIrecoveryforalvimopanversusplacebowasnotstatistically
signiﬁcantinthistrialinpatientswhodidnotreceiveopioid-
based IV-PCA [76].
Retrospective analyses of the phase III alvimopan trials
have demonstrated additional beneﬁts to the patient and
the healthcare system. Patients receiving alvimopan 12mg
were less likely to experience POI-related morbidity than
patientsreceivingplacebo(oddsratio=0.44, P ≤ .001)[84].
Furthermore,alvimopanpatientsweresigniﬁcantlylesslikely
to require postoperative NGT insertion and had signiﬁcantly
fewer episodes of prolonged hospital stays or readmission to
the hospital for POI symptoms (P ≤ .001). These reductions
translate into a beneﬁt not only to the patient but to the
healthcare system as well. In a recent post hoc economic
analysis of the phase III alvimopan trials the mean estimated
hospital cost was $879–$977 less for patients who received
alvimopan compared with placebo [85].
2.4. What Would a Best Practices Plan Look Like?Multimodal
pathways to accelerate GI recovery and reduce the
postoperative length of stay generally include early planned
discharge, encouragement of early mobilization, early oral
nutrition, and no routine NGT use postoperatively [86, 87].
Patients undergoing these “fast-track” postoperative
management protocols consistently have a shorter hospital
length of stay than patients receiving traditional care (e.g.,
NGT in place until bowel sounds return or the passage
of ﬂatus) [88–91]. Gum chewing, a type of sham feeding,
reduced the time to ﬁrst ﬂatus and ﬁrst bowel movement
after laparoscopic colectomy in several small, randomized,
prospective studies [92–94] and 2 metaanalyses [95].
However, results have not been consistent [96]a n daw e l l -
controlled, rigorously designed trial is needed to further
clarify the eﬀect of gum chewing on GI recovery. Laxatives,
as part of a multimodal rehabilitation regimen, were also
associated with early GI recovery and hospital discharge
in prospective studies [97–99]. However, few randomized
controlled studies of laxatives alone (i.e., not as part of a
multimodal regimen) have been conducted, and laxatives are
generally not used for the management of POI after major
abdominal surgery such as bowel resection [50, 100].
Administration of pharmacologic agents initiated in the
perioperative period and continued through the postop-
erative period (e.g., epidural analgesia, PAM-OR antago-
nists, NSAIDS, and gabapentin) may contribute to faster GI
recovery in the postoperative period [17, 29, 101].
2.5. How Can We Get Our Institution on Track with the Best
Practice Routines for BR and POI Prevention?
Several key components are important elements to be
considered and included in an anesthesia and surgery line of
service for BR (Table 1)[ 11, 27, 35, 43, 50, 83, 86, 89, 95,
102–115]. These suggestions have been shown to contribute
to earlier return of GI function either as independent or
component variables in similar multimodal management
pathways. These factors should be considered for all patients.
3. Conclusions
Postoperative GI dysmotility is the primary determinate of
length of hospital stay after abdominal surgery [116, 117].
In the absence of multimodal treatment programs, mean
hospital stay after colorectal surgery may be as long as 10
days [118–120]. A study of patients undergoing abdominal
surgery revealed that the type and severity of the side eﬀects
of pain medications administered were more important to
patients than postoperative pain control, highlighting the
eﬀect of POI on patient satisfaction [121]. Management of
POI and earlier return of GI function may result in improved
patient satisfaction and decreased length of hospital stay.
Multimodal techniques reduce the incidence and dura-
tion of POI. However, these multimodal techniques require
the cooperation of the entire surgical team and collective
knowledgeofpathways,protocols,andpharmacologicagents
with potential to manage POI. It is essential that anesthesiol-
ogists play a critical role in the surgical team for providing
optimal preoperative, perioperative, and postoperative care.
Furthermore, through preoperative discussions and patient
assessment, it may be possible to enroll a patient in an
individualized multifaceted approach for optimal recovery.
It is vital that patients receive high-quality pain relief with
minimal impairment of GI function, and that all patients are
managed eﬀectively to ensure a rapid return to their normal
lifestyle.
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